4/A: Ionis Pharmaceuticals EVP Eric Swayze Amends Form 4 After Stock Sale
SEC Filing
Eric Swayze, EVP of Research at Ionis Pharmaceuticals, amends a previous Form 4 filing to correct the number of shares sold on February 2, 2024.
Summary
- Eric Swayze, the EVP of Research at Ionis Pharmaceuticals, filed an amended Form 4 to correct a previous transaction.
- The amendment corrects the number of shares sold on February 2, 2024.
- The corrected filing shows that 1,940 shares of common stock were sold at a weighted average price of $49.5613.
- Following the transaction, Swayze beneficially owns 34,291 shares.
- The shares were sold in multiple transactions at prices ranging from $49.55 to $49.57 inclusive.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading disclosures, providing transparency into the transactions of company executives and directors. This amendment highlights the importance of accurate reporting and the potential for corrections.
Stakeholder Impact
- The correction of the Form 4 filing ensures accurate information for shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original transaction and original Form 4 filing. |
| 02/02/2024 | Date of amended transaction. |
| 09/04/2024 | Date of amended filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.